Utilization and Safety of Ipilimumab Plus Nivolumab in a Real-World Cohort of Metastatic Renal Cell Carcinoma Patients-Reference-Cited by-同舟云学术

Utilization and Safety of Ipilimumab Plus Nivolumab in a Real-World Cohort of Metastatic Renal Cell Carcinoma Patients

Published:2021-12 Issue: Volume: Page:
ISSN:1558-7673
Container-title:Clinical Genitourinary Cancer
language:en
Short-container-title:Clinical Genitourinary Cancer

Author:

Thana Myuran^ORCID,Basappa Naveen S.,Ghosh Sunita,Kollmannsberger Christian K.,Heng Daniel Y.C.,Hansen Aaron R.,Graham Jeffery,Soulières Denis,Reaume Martin Neil,Lalani Aly-Khan A.^ORCID,Castonguay Vincent^ORCID,Bjarnason Georg A.^ORCID,Patenaude François,Breau Rodney H.,Pouliot Frédéric,Kapoor Anil^ORCID,Wood Lori A.

Publisher

Elsevier BV

Subject

Urology,Oncology

Reference11 articles.

1. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma;Motzer;N Engl J Med,2018

2. Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial;Motzer;J Immunother Cancer,2020

3. Determining Generalizability of the Canadian kidney cancer information system (CKCis) to the entire Canadian kidney cancer Population;Tajzler;Can Urol Assoc J,2020

4. External validation and comparison with other models of the international metastatic renal-cell carcinoma database consortium prognostic model: a population-based study;Heng;Lancet Oncol,2013

5. Outcomes of first-line (1 L) immuno-oncology (IO) combination therapies in metastatic renal cell carcinoma (mRCC): results from the International mRCC database consortium (IMDC);Gan;J Clin Oncol,2021

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Exploring oncogenes for renal clear cell carcinoma based on G protein-coupled receptor-associated genes;Discover Oncology;2023-10-10

2. Survival and Early Death Within Three Months from the Start of Immune Checkpoint Inhibitors in Patients With Different Types of Cancer;Anticancer Research;2022-05-31

3. Compassionate Use Program of Ipilimumab and Nivolumab in Intermediate or Poor Risk Metastatic Renal Cell Carcinoma: A Large Multicenter Italian Study;Cancers;2022-05-04

4. A probiotic supplement boosts response to cancer immunotherapy;Nature Medicine;2022-03-14